title: [Conservative treatment undifferentiated neuroendocrine tumors of the anal canal: two cases].
abstract: Undifferentiated neuroendocrine tumors are rare, and are characteristically aggressive with a poor prognosis. Most patients have metastatic disease at diagnosis, and cannot undergo curative surgical treatment. A chemotherapy regimen combining etoposide plus cisplatin is currently considered to be the reference treatment. We report two cases of poorly differentiated neuroendocrine tumors localized in the anal canal and treated by chemotherapy and radiotherapy resulting in prolonged complete local remission and preventing extended surgical excision.
authors.affiliation: Service d'Hépato-Gastroentérologie et d'oncologie digestive, Fédération des spécialités digestives, Hôpital Ambroise Paré, Boulogne-Billancourt, France. celine.lepere@apr.aphp.fr
authors.forename: Céline
authors.initials: C
authors.lastname: Lepère
authors.forename: Suzy
authors.initials: S
authors.lastname: Rakotomalala
authors.forename: Frédérique
authors.initials: F
authors.lastname: Maindrault-Goebel
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mitry
authors.forename: Jean-Nicolas
authors.initials: JN
authors.lastname: Vaillant
authors.forename: Catherine
authors.initials: C
authors.lastname: Julie
authors.forename: Yves
authors.initials: Y
authors.lastname: Otmezguine
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D001003:Anal Canal / Q000473:pathology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D001706:Biopsy; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D002945:Cisplatin